Get the Stockscreener App
2.14
2.94%
-0.07
Akebia Therapeutics Inc stock is traded at $2.14, with a volume of 2.74M.
It is down -2.94% in the last 24 hours and down -24.20% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.21
Open:
$2.2
24h Volume:
2.74M
Relative Volume:
0.70
Market Cap:
$568.74M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-7.6429
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-32.33%
1M Performance:
-24.20%
6M Performance:
-12.45%
1Y Performance:
+26.92%
1-Day Range:
$2.065
$2.22
1-Week Range:
$2.065
$3.20
52-Week Range:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.145 | 585.97M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
144.46 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.43 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.3824 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.14 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics Securities Lawsuit Investigation - Claim Depot
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockDip Buying & Long-Term Capital Growth Strategies - newser.com
Live market analysis of Akebia Therapeutics Inc.Market Activity Recap & Safe Entry Trade Reports - newser.com
How high can Akebia Therapeutics Inc. stock goQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
Will earnings trigger a reversal in Akebia Therapeutics Inc.2025 Year in Review & Weekly Top Gainers Alerts - newser.com
Akebia Therapeutics Inc. stock retracement – recovery analysisEarnings Miss & Daily Volume Surge Trade Alerts - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth fundsGap Down & Free Long-Term Investment Growth Plans - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stockWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
Wall Street Zen Upgrades Akebia Therapeutics (NASDAQ:AKBA) to "Strong-Buy" - MarketBeat
HC Wainwright Issues Pessimistic Forecast for AKBA Earnings - MarketBeat
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growthJuly 2025 Macro Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat
Is this a good reentry point in Akebia Therapeutics Inc.2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
How Akebia Therapeutics Inc. stock reacts to job market data2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Akebia Therapeutics (AKBA) Valuation in Focus After VALOR Trial Decision Alters Vafseo Strategy - Sahm
Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure - Markets Mojo
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat
How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener
HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks
Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks
Will Akebia Therapeutics Inc. stock benefit from sector rotationJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):